S. Res. 464 is a Senate resolution that designates September 2025 as “National Cholesterol Education Month” and September 30, 2025, as “LDL–C Awareness Day,” and it expressly encourages individuals to know their low‑density lipoprotein cholesterol (LDL–C) number.
The resolution’s preamble compiles published, population‑level findings — prevalence estimates, care‑gap statistics, and disparity signals — and calls attention to existing programs such as Million Hearts.
Because the measure is a nonbinding resolution, it does not create regulatory requirements, funding streams, reimbursement changes, or clinical mandates. Its practical significance lies in signaling Senate attention to lipid management, providing an anchor for public‑health outreach, and supplying congressional language advocates and agencies can cite when seeking to expand screening, education, or targeted interventions.
At a Glance
What It Does
The resolution formally designates a month and a day for cholesterol awareness, compiles factual findings about LDL–C and cardiovascular risk, and encourages individuals to know their LDL–C level. It recognizes gaps in post‑event testing and treatment goal attainment but does not direct federal agencies or appropriate funds.
Who It Affects
Public‑health organizations, patient advocacy groups, clinicians, state and local health departments, and programs focused on cardiovascular prevention (for example, Million Hearts) are the primary audiences who can use the designation for outreach. Payers and clinical providers may face increased demand for testing and counseling but receive no new statutory obligations.
Why It Matters
The resolution codifies specific statistics and disparities into congressional record language that advocacy groups and agencies can cite when seeking programmatic or funding changes. Because it is symbolic rather than prescriptive, its effect will depend on whether stakeholders use the designation to drive measurable screening and treatment efforts.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is a short, nonbinding Senate resolution that combines a set of findings with four short resolve clauses. The findings list evidence and statistics about cardiovascular disease, the role of LDL‑C and lipoprotein(a), and observed gaps in testing and treatment.
The resolve clauses (1) encourage individuals to know their LDL‑C number, (2) designate September 2025 as National Cholesterol Education Month, (3) designate September 30, 2025, as LDL‑C Awareness Day, and (4) recognize the urgent need for screening and treating elevated LDL‑C to reduce cardiovascular events.
Because the resolution does not appropriate money or amend any statute, it imposes no legal obligations on providers, payers, or federal agencies. Its value is rhetorical and programmatic: public‑health offices, nonprofit groups, and professional societies are the actors most likely to convert the designation into campaigns, screening events, or educational materials.
The resolution’s citation of specific care‑gap statistics gives advocates concrete figures to use when asking Congress, HHS, or payers to prioritize lipid screening and treatment initiatives.The preamble raises several operationally important points that the resolution does not itself act on. It distinguishes lipoprotein(a) — flagged as predominantly genetic — from LDL‑C, which the text describes as modifiable.
It also documents geographic and racial differences in outcomes and testing rates; those findings point to where programs should focus but do not create targeting requirements or funding. Practically, the resolution can prompt voluntary actions: states or health systems may run awareness campaigns in September; clinicians may intensify LDL‑C checks after hospital discharge; insurers may reassess coverage of lipid testing and newer lipid‑lowering therapies if advocacy pressure grows.Finally, the resolution links to existing infrastructure by noting Million Hearts.
That reference suggests a ready operational pathway for stakeholders who want to turn awareness into measurable prevention activities, but the resolution itself leaves the scope, scale, and financing of any follow‑up to separate programmatic or legislative action.
The Five Things You Need to Know
The resolution formally designates September 2025 as "National Cholesterol Education Month.", The resolution designates September 30, 2025, as "LDL–C Awareness Day.", It explicitly encourages all individuals in the United States to know their LDL‑C number but creates no legal mandates or funding.
The preamble lists concrete care‑gap statistics: over 25.5% of U.S. adults have high LDL‑C, 71% of high‑risk hypercholesterolemia patients never achieve guideline LDL‑C thresholds, and only 33% of individuals with atherosclerotic cardiovascular disease on statins reach LDL‑C goals.
The resolution notes testing shortfalls after hospital discharge — only 27% receive an LDL‑C test within 90 days — and cites higher cardiovascular mortality and prevalence in rural areas and lower post‑discharge testing rates among African‑American adults.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings: epidemiology, risk factors, and care gaps
The preamble aggregates published evidence and survey‑style findings: cardiovascular disease is the leading cause of death; projected increases through 2060; higher rural mortality and prevalence; the roles of LDL‑C and lipoprotein(a); and specific performance gaps in testing and treatment. For implementers, these findings function like a compact evidence brief — useful for grant applications, public messaging, or justifying program priorities — but they do not change clinical guidance or payment policy.
Encouragement to individuals to know their LDL‑C
This clause urges all individuals to learn their LDL‑C number. It creates a voluntary, informational obligation aimed at increasing patient awareness and presumably prompting patient‑initiated testing or clinician counseling. Because the clause is hortatory, it places responsibility on outreach actors (public health agencies, clinicians, nonprofits) to turn awareness into action rather than on any regulated entity.
Designation of awareness month and awareness day
These two clauses make the designations calendar‑specific: a month and a single day in 2025. That calendar anchoring makes it easier for organizations to plan time‑bound campaigns, fundraising, or screening events. The resolution does not create recurring or permanent annual observances beyond these 2025 designations, nor does it instruct federal agencies to produce materials or reports tied to the dates.
Recognition of need for screening and treatment
The final clause states a congressional recognition of an 'urgent need' for screening and treating elevated LDL‑C to reduce cardiovascular events. This language is significant for advocacy because congressional recognition can be cited in appropriations requests or rulemaking comments, but by itself it imposes no deadlines, metrics, or enforcement mechanisms for testing, treatment uptake, or disparity reduction.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients at elevated cardiovascular risk — the resolution raises public awareness and may increase screening and treatment uptake if leveraged by health systems or insurers, potentially improving prevention and outcomes for people with high LDL‑C.
- Public‑health and advocacy groups — the designated month and day provide an official hook for fundraising, media outreach, and coordinated screening campaigns, and the resolution’s statistics give advocates concrete language to support program proposals.
- Primary care and cardiology practices — increased patient awareness can drive demand for lipid testing and management services, offering clinicians opportunities to close care gaps and engage patients in secondary prevention.
- Programs focused on underserved areas (rural health departments, community health centers) — the resolution highlights rural and racial disparities and can be used to justify targeted outreach or grant applications addressing those gaps.
Who Bears the Cost
- State and local health departments and nonprofits — if they choose to run awareness or screening campaigns tied to the designation, they will likely absorb planning, outreach, and operational costs because the resolution provides no federal funding.
- Clinical laboratories and outpatient clinics — increased LDL‑C testing and follow‑up visits could create incremental operational demand and billing activity, with associated staffing and supply costs.
- Payers (Medicaid programs and insurers) — if awareness drives higher testing and initiation of lipid‑lowering therapies, payers may face increased near‑term expenditures; coverage decisions for newer therapies could become more contested.
- Health systems serving rural and minority populations — they may be expected to respond to newly publicized disparities, which can require investment in outreach, care coordination, and telehealth capacity without guaranteed new revenue.
Key Issues
The Core Tension
The central dilemma is symbolic awareness versus operational commitment: the resolution aims to increase attention to a modifiable risk factor, but without funding or mandates it may drive demand for testing and treatment that the current delivery system and payer landscape are not uniformly prepared to meet, potentially widening access gaps even as it raises overall awareness.
The resolution is expressly symbolic: it compiles findings and urges action but does not allocate funds, change coverage rules, or instruct federal agencies to implement programs. That makes its near‑term policy impact contingent on follow‑on activity by agencies, appropriators, payers, and health systems.
Absent additional legislation or appropriation, the designation will mainly serve as advocacy language.
The bill also raises implementation questions the text does not answer. It flags lipoprotein(a) as predominantly genetic but does not recommend screening thresholds or follow‑up protocols; it documents disparities and testing shortfalls without prescribing accountability measures; and it highlights gaps in post‑discharge LDL‑C testing but does not identify who should be responsible for closing that gap.
Those omissions create space for stakeholders to propose interventions, but they also leave open the risk that awareness campaigns increase demand without ensuring equitable access to testing and effective treatment.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.